The Zika Virus Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Zika Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Zika Virus Infections. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued products.

GlobalData tracks 119 drugs in development for Zika Virus Infections by 103 companies/universities/institutes. The top development phase for Zika Virus Infections is preclinical with 69 drugs in that stage. The Zika Virus Infections pipeline has 85 drugs in development by companies and 34 by universities/ institutes. Some of the companies in the Zika Virus Infections pipeline products market are: National Institute of Allergy and Infectious Diseases, Ennaid Therapeutics and Plex Pharmaceuticals.

The key targets in the Zika Virus Infections pipeline products market include Zika Virus Envelope Protein (E), Nonstructural Protein 1 (NS1), and Premembrane Protein (prM).

The key mechanisms of action in the Zika Virus Infections pipeline product include Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Antagonist with one drug in Preclinical. The Zika Virus Infections pipeline products include seven routes of administration with the top ROA being Oral and 17 key molecule types in the Zika Virus Infections pipeline products market including Small Molecule, and Subunit Vaccine.

Zika Virus Infections overview

Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can also be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

For a complete picture of Zika Virus Infections’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.